Is the US AIDS Drug Assistance Program Cost-effective?
- 395 Downloads
Each year, the US AIDS drug assistance program (ADAP) provides access to prescription drugs—including antiretrovirals—to more than 110,000 persons living with HIV (PLWH) who lack adequate medical insurance. PLWH on effective antiretroviral therapy live longer lives, with enhanced quality of life, and are less likely to transmit HIV to others. There are thus significant benefits associated with the ADAP program. But there also are substantial costs. A mathematical model was used to assess the cost-effectiveness of the US ADAP program. Findings indicate that by providing antiretrovirals to underinsured persons, the ADAP program prevented 3,191 secondary infections and saved 24,922 quality-adjusted life years in 2008. The net cost per quality-adjusted life year saved was $11,955, which suggests that the ADAP program is cost-effective by conventional standards.
KeywordsAIDS drug assistance program Antiretroviral therapy Cost-effectiveness
This study was supported by center grant P30-MH52776 from the National Institute of Mental Health (NIMH), by NIMH grant R01-MH077511, and by a grant from the Robert Wood Johnson Foundation.
- 1.Kates J, Penner MC, Crutsinger-Perry B, Leggoe AW, Singleton N. National ADAP monitoring project: annual report. The Henry J. Kaiser Family Foundation (KFF) and The National Alliance of State and Territorial AIDS Directors (NASTAD) (2005).Google Scholar
- 2.Carbaugh AL, Kates J, Crutsinger-Perry B, Ginsburg B, Penner MC. National ADAP monitoring project: annual report. The Henry J. Kaiser Family Foundation (KFF) and The National Alliance of State and Territorial AIDS Directors (NASTAD) (2009).Google Scholar
- 3.Kaiser Family Foundation. AIDS drug assistance programs (ADAPs). 2009 Fact Sheet #1584. Accessed 2 July 2011 http://www.kff.org/hivaids/upload/1584_10.pdf.
- 5.Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection Med J Aust. 2007;186:146–51.Google Scholar
- 7.Burman, WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW, for the SMART Study Group. The impact of episodic CD4 cell count–guided antiretroviral therapy on quality of life. J Acquir Immune Defic Synd 2008;47:185–193.Google Scholar
- 12.Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Med Decis Making 2012; 32(3):459–69. http://mdm.sagepub.com/content/early/2012/01/03/0272989X11431609.full.pdf.
- 15.Centers for Disease Control and Prevention. Vital signs: HIV prevention through care and treatment, United States. MMWR. 2011;60:1618–23.Google Scholar
- 21.Schrappe M, Lauterbach K. Systematic review on the cost-effectiveness of public health interventions for HIV prevention in industrialized countries. AIDS 1998;12 (suppl A):S231–S238.Google Scholar
- 24.Kaiser Family Foundation. AIDS drug assistance programs (ADAPs) with waiting lists or other cost-containment strategies, as of May 2011. Accessed 15 June 2011http://www.statehealthfacts.org/comparemaptable.jsp?ind=552&cat:11&sub=204&yr=1&typ=5.
- 25.Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR. 2011;60:689–93.Google Scholar